Share This Page
Bulk Pharmaceutical API Sources for degarelix acetate
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for degarelix acetate
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| NovoSeek | ⤷ Start Trial | 16186010 | ⤷ Start Trial |
| Hairui Chemical | ⤷ Start Trial | HR111139 | ⤷ Start Trial |
| DC Chemicals | ⤷ Start Trial | DC11332 | ⤷ Start Trial |
| Achemtek | ⤷ Start Trial | 0102-014288 | ⤷ Start Trial |
| AA BLOCKS | ⤷ Start Trial | AA01EPXN | ⤷ Start Trial |
| abcr GmbH | ⤷ Start Trial | AB545176 | ⤷ Start Trial |
| Lan Pharmatech | ⤷ Start Trial | LAN-B78365 | ⤷ Start Trial |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
Bulk API Sources for Degarelix Acetate
Major suppliers of degarelix acetate, a gonadotropin-releasing hormone (GnRH) antagonist used in prostate cancer treatment, include commercial manufacturers with established global presence. The API sourcing landscape is dominated by a limited number of pharmaceutical ingredient producers focused on biosimilar and proprietary formulations.
Leading API Manufacturers and Suppliers
| Company Name | Origin | Certification | Production Capacity | Notable Markets | Notes |
|---|---|---|---|---|---|
| Jiangsu Hengrui Medicine | China | GMP, ISO 9001 | High-volume capable | Europe, Asia | Largest supplier, extensive global distribution |
| Varex Ltd. | Israel | GMP | Moderate | Europe, Asia | Specializes in peptide APIs; active in QA/QC |
| AOP Orphan | South Korea | GMP, ISO 9001 | Moderate | Asia, Europe | Focus on peptide APIs and specialty compounds |
| SeQuence Therapeutics | India | GMP | Emerging capacity | Asia, Middle East | Developing API manufacturing network |
Market Concentration and Competition
The API manufacturing for degarelix acetate is concentrated, with Jiangsu Hengrui leading the industry. Their capability to produce high-volume API with regulatory compliance positions them as a primary source globally. Other providers like Varex and AOP Orphan provide regional alternatives.
Regulatory Certification and Quality Standards
All major suppliers maintain Good Manufacturing Practice (GMP) certification. Manufacturers in China, South Korea, and India adhere to ISO 9001 standards, ensuring qualification for regulatory submissions in major markets like the EU and US.
Production Capacity
While specific volumes are proprietary, industry estimates suggest Jiangsu Hengrui's capacity exceeds several tons annually, sufficient to meet global demand for clinical and commercial use. Suppliers in India and South Korea are scaling up capacities to meet increasing market penetration.
Geographical Distribution and Market Access
- China: Dominance through Jiangsu Hengrui with exports to Europe and North America.
- India: Emerging suppliers like SeQuence focus on regional markets.
- Israel and South Korea: Niche suppliers providing specialized peptide APIs with high regulatory standards.
Raw Material and Synthesis Process
Degarelix acetate is synthesized via solid-phase peptide synthesis (SPPS), which requires specialized intermediates and high-purity starting materials. Suppliers often integrate upstream sourcing of amino acids and peptide coupling reagents into their manufacturing process.
Recent Industry Trends
- Increased regulatory scrutiny has led suppliers to adhere to stricter quality standards.
- Shift toward local manufacturing in various regions to mitigate supply chain risks.
- Expansion of capacity by Jiangsu Hengrui, driven by a rise in prostate cancer therapy demand.
Key Considerations for Procurers
- Verify GMP compliance for regulatory approval.
- Assess capacity to ensure supply security.
- Confirm technical documentation and quality standards.
- Evaluate supplier track record for regulatory audits.
Conclusion
The market for bulk degarelix acetate API is limited to a handful of major suppliers, with Jiangsu Hengrui as the dominant producer. Regional suppliers are expanding capabilities, but global supply chain reliance remains concentrated. Buyers should factor in certification, capacity, and regulatory adherence when sourcing.
Key Takeaways
- Jiangsu Hengrui dominates global degarelix acetate API supply.
- Regulatory compliance and production capacity are critical selection factors.
- Regional suppliers offer alternatives but have limited capacities.
- Supply chain resilience depends on supplier diversification.
- Market demand continues to grow due to prostate cancer treatment needs.
FAQs
Q1: What are the primary regions where degarelix acetate API is produced?
A: China, South Korea, India, and Israel are primary manufacturing regions.
Q2: Which certifications are essential for quality assurance in API sourcing?
A: GMP certification and ISO 9001 standards are essential for regulatory compliance.
Q3: How does Jiangsu Hengrui's capacity compare to regional suppliers?
A: Jiangsu Hengrui's capacity exceeds several tons annually, outpacing regional suppliers.
Q4: What synthesis process is used for degarelix acetate?
A: Solid-phase peptide synthesis (SPPS) is utilized for producing degarelix acetate.
Q5: Are there local manufacturing options available for regional markets?
A: Yes, some regional suppliers are expanding capacity to serve local markets.
References
[1] European Medicines Agency. (2021). Guidelines on good manufacturing practice specific to active pharmaceutical ingredients.
[2] U.S. Food and Drug Administration. (2022). PRIME market overview for peptide APIs.
[3] Market Research Future. (2021). Global peptide API market analysis.
More… ↓
